https://www.biospace.com/akero-therapeutics-announces-initiation-of-phase-3-synchrony-outcomes-trial-of-efruxifermin-in-patients-with-compensated-cirrhosis-f4-due-to-mash
Akero Therapeutics, Inc. announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin in patients...
akerotherapeuticsannouncesinitiationphase